Immunological Evaluation and Comparison of Different EV71 Vaccine Candidates

被引:32
作者
Chou, Ai-Hsiang [1 ]
Liu, Chia-Chyi [1 ]
Chang, Jui-Yuan [1 ]
Lien, Shu-Pei [1 ]
Guo, Meng-Shin [1 ]
Tasi, Hau-Pong [1 ]
Hsiao, Kuang-Nan [1 ]
Liu, Shih-Jen [1 ]
Sia, Charles [1 ]
Wu, Suh-Chin [1 ,2 ]
Lee, Min-Shi [1 ]
Hsiao, Chia-Hsin [1 ]
Wang, Jen-Ren [3 ]
Chow, Yen-Hung [1 ]
Chong, Pele [1 ,4 ]
机构
[1] Natl Hlth Res Inst, Natl Inst Infect Dis & Vaccinol, Vaccine R&D Ctr, Zhunan Township, Miaoli County, Taiwan
[2] Natl Tsing Hua Univ, Inst Biotechnol, Hsinchu, Taiwan
[3] Natl Cheng Kung Univ, Coll Med, Dept Med Lab Sci & Biotechnol, Tainan 70101, Taiwan
[4] China Med Univ, Grad Inst Immunol, Taichung, Taiwan
来源
CLINICAL & DEVELOPMENTAL IMMUNOLOGY | 2012年
关键词
ENTEROVIRUS; 71; VACCINE; INACTIVATED VACCINE; NEWBORN MICE; INFECTION; LETHAL; IDENTIFICATION; IMMUNIZATION; PROTECTION; EVOLUTION; STRAIN;
D O I
10.1155/2012/831282
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Enterovirus 71 (EV71) and coxsackievirus A16 (CVA16) are major causative agents of hand, foot, and mouth diseases (HFMDs), and EV71 is now recognized as an emerging neurotropic virus in Asia. Effective medications and/or prophylactic vaccines against HFMD are not available. The current results from mouse immunogenicity studies using in-house standardized RD cell virus neutralization assays indicate that (1) VP1 peptide (residues 211-225) formulated with Freund's adjuvant (CFA/IFA) elicited low virus neutralizing antibody response (1/32 titer); (2) recombinant virus-like particles produced from baculovirus formulated with CFA/IFA could elicit good virus neutralization titer (1/160); (3) individual recombinant EV71 antigens (VP1, VP2, and VP3) formulated with CFA/IFA, only VP1 elicited antibody response with 1/128 virus neutralization titer; and (4) the formalin-inactivated EV71 formulated in alum elicited antibodies that cross-neutralized different EV71 genotypes (1/640), but failed to neutralize CVA16. In contrast, rabbits antisera could cross-neutralize strongly against different genotypes of EV71 but weakly against CVA16, with average titers 1/6400 and 1/32, respectively. The VP1 amino acid sequence dissimilarity between CVA16 and EV71 could partially explain why mouse antibodies failed to cross-neutralize CVA16. Therefore, the best formulation for producing cost-effective HFMD vaccine is a combination of formalin-inactivated EV71 and CAV16 virions.
引用
收藏
页数:8
相关论文
共 31 条
[1]   Formalin-inactivated vaccine provokes cross-protective immunity in a mouse model of human enterovirus 71 infection [J].
Bek, Emily Jane ;
Hussain, Khairunnisa Mohamed ;
Phuektes, Patchara ;
Kok, Chee Choy ;
Gao, Qiang ;
Cai, Fang ;
Gao, Zhenglun ;
McMinn, Peter Charles .
VACCINE, 2011, 29 (29-30) :4829-4838
[2]   Molecular epidemiology of human enterovirus 71 in the United Kingdom from 1998 to 2006 [J].
Bible, Jon M. ;
Iturriza-Gomara, Miren ;
Megson, Brian ;
Brown, David ;
Pantelidis, Panagiotis ;
Earl, Pam ;
Bendig, Justin ;
Tong, C. Y. William .
JOURNAL OF CLINICAL MICROBIOLOGY, 2008, 46 (10) :3192-3200
[3]   Complete nucleotide sequence of enterovirus 71 is distinct from poliovirus [J].
Brown, BA ;
Pallansch, MA .
VIRUS RESEARCH, 1995, 39 (2-3) :195-205
[4]   Hepatitis and death following vaccination with 17D-204 yellow fever vaccine [J].
Chan, RC ;
Penney, DJ ;
Little, D ;
Carter, IW ;
Roberts, JA ;
Rawlinson, WD .
LANCET, 2001, 358 (9276) :121-122
[5]   Phylogenetic designation of enterovirus 71 genotypes and subgenotypes using complete genome sequences [J].
Chan, Yoke-Fun ;
Sam, I-Ching ;
AbuBakar, Sazaly .
INFECTION GENETICS AND EVOLUTION, 2010, 10 (03) :404-412
[6]   Selection and characterization of vaccine strain for Enterovirus 71 vaccine development [J].
Chang, Jui-Yuan ;
Chang, Cheng-Peng ;
Tsai, Hutchinson Hau-Pong ;
Lee, Chen-Dou ;
Lian, Wei-Cheng ;
Ih-Jen-Su ;
Sai, I-Hsi ;
Liu, Chia-Chyi ;
Chou, Ai-Hsiang ;
Lu, Ya-Jung ;
Chen, Ching-Yao ;
Lee, Pi-Hsiu ;
Chiang, Jen-Ron ;
Chong, Pele Choi-Sing .
VACCINE, 2012, 30 (04) :703-711
[7]   Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal, challenge [J].
Chung, Yao-Chi ;
Ho, Mei-Shang ;
Wu, Jaw-Chin ;
Chen, Wei-Jheng ;
Huang, Jen-Huang ;
Chou, Szu-Ting ;
Hu, Yu-Chen .
VACCINE, 2008, 26 (15) :1855-1862
[8]   Surveillance of suspected poliomyelitis in Albania, 1980-1995: suggestion of increased risk of vaccine associated poliomyelitis [J].
Diamanti, E ;
Ibrahimi, B ;
Tafaj, F ;
Mezini, E ;
Dodbiba, A ;
Dobi, V ;
Catone, S ;
Genovese, D ;
Simeoni, P ;
Fiore, L .
VACCINE, 1998, 16 (9-10) :940-948
[9]   Immunoprotection elicited by an enterovirus type 71 experimental inactivated vaccine in mice and rhesus monkeys [J].
Dong, Chenghong ;
Liu, Longding ;
Zhao, Hongling ;
Wang, Jingjing ;
Liao, Yun ;
Zhang, Xuemei ;
Na, Ruixiong ;
Liang, Yan ;
Wang, Lichun ;
Li, Qihan .
VACCINE, 2011, 29 (37) :6269-6275
[10]   Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide [J].
Foo, Damian Guang Wei ;
Alonso, Sylvie ;
Chow, Vincent Tak Kwong ;
Poh, Chit Laa .
MICROBES AND INFECTION, 2007, 9 (11) :1299-1306